https://scholars.lib.ntu.edu.tw/handle/123456789/582084
標題: | A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection | 作者: | Tong M.J. Hsu L. Hsien C. JIA-HORNG KAO Durazo F.A. Saab S. Blatt L.M. |
關鍵字: | Basal core promoter mutant; Chronic hepatitis; Cirrhosis; Genotype; HBeAg; HBV DNA; Immune tolerant; Inactive carriers; Precore mutant | 公開日期: | 2010 | 卷: | 4 | 期: | 2 | 起(迄)頁: | 516-522 | 來源出版物: | Hepatology International | 摘要: | Purpose: Hepatitis B viral markers may be useful for predicting outcomes such as liver-related deaths or development of hepatocellular carcinoma. We determined the frequency of these markers in different clinical stages of chronic hepatitis B infection. Methods: We compared baseline hepatitis B viral markers in 317 patients who were enrolled in a prospective study and identified the frequency of these tests in immune-tolerant (IT) patients, in inactive carriers, and in patients with either hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis or cirrhosis. Results: IT patients were youngest (median age 27 years) and HBeAg-negative patients with cirrhosis were oldest (median age 58 years) (p = 0.03 to <0.0001). The male to female ratio was similar both in IT patients and in inactive carriers, but there was a male preponderance both in patients with chronic hepatitis and in patients with cirrhosis (p < 0.0001). The A1896 precore mutants were most prevalent in inactive carriers (36.4%) and HBeAg-negative patients with chronic hepatitis (38.8%; p < 0.0001), and the T1762/A1764 basal core promoter mutants were most often detected in HBeAg-negative patients with cirrhosis (65.1%; p = 0.02). Genotype A was detected only in 5.3% of IT patients, and genotype B was least often detected in both HBeAg-Positive patients with chronic hepatitis and cirrhosis (p = 0.03). The hepatitis B viral DNA levels were lowest in inactive carriers (2.69 log10 IU/mL) and highest in IT patients (6.80 log 10 IU/mL; p = 0.02 to <0.0001). At follow-up, HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for 57 of 64 (89.1%) liver-related deaths (p < 0.0001). Conclusion: Differences in baseline hepatitis B viral markers were detected in patients in various clinical stages of hepatitis B virus infection. HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for the majority of the liver-related fatalities. ? 2010 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955513644&doi=10.1007%2fs12072-010-9179-1&partnerID=40&md5=40808b774dd139871cb20b5daa3957db https://scholars.lib.ntu.edu.tw/handle/123456789/582084 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-010-9179-1 | SDG/關鍵字: | alanine aminotransferase; albumin; aspartate aminotransferase; bilirubin; biological marker; hepatitis B(e) antigen; virus DNA; adult; article; comparative study; controlled study; death; female; follow up; genotype; health status; hepatitis B; human; immunological tolerance; liver cirrhosis; major clinical study; male; priority journal; promoter region; prospective study; virology; virus mutant |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。